Chunghwa Chemical Synthesis & Biotech : Resolution of the Board of Directors for convening the 2022 Annual General Shareholders' Meeting. (Adding Matters for Discussion)
Provided by: Chunghwa Chemical Synthesis & Biotech Co.,Ltd
SEQ_NO
4
Date of announcement
2022/03/08
Time of announcement
20:42:22
Subject
Resolution of the Board of Directors for convening the
2022 Annual General Shareholders' Meeting. (Adding Matters
for Discussion)
Date of events
2022/03/08
To which item it meets
paragraph 17
Statement
1.Date of the board of directors' resolution: 2022/03/08
2.Shareholders meeting date:2022/05/25
3.Shareholders meeting location:
4F, No. 2, Xuzhou Road, Zhongzheng District, Taipei City
(Room 401, NTUH International Convention Center)
4.Shareholders meeting will be held by means of (physical shareholders
meeting/ visual communication assisted shareholders meeting /
visual communication shareholders meeting):physical shareholders
meeting
5.Cause for convening the meeting (1)Reported matters:
1.2021 Business Report.
2.Audit Committee' Audit Report on the 2021 Financial Statements.
3.2021 distribution for director's and employee's compensation.
4.Other report.
6.Cause for convening the meeting (2)Acknowledged matters:
1.2021 business report and financial statements.
2.Distribution of 2021 earnings.
7.Cause for convening the meeting (3)Matters for Discussion:
1.Partial amendments to the Company's Corporate Charter. (newly added)
2.Partial amendments to the Procedures for Acquisition or Disposal
of Assets.(newly added)
3.Proposed private placement of ordinary shares or issuance of
domestic convertible corporate bonds (including secured or
unsecured bonds).(newly added)
8.Cause for convening the meeting (4)Election matters:
To elect Directors (including independent directors)
9.Cause for convening the meeting (5)Other Proposals:
Other matters for discussion: To release non-compete restrictions
on newly elected directors and authorized representatives.
10.Cause for convening the meeting (6)Extemporary Motions:None
11.Book closure starting date:2022/03/27
12.Book closure ending date:2022/05/25
13.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Chunghwa Chemical Synthesis & Biotech Co. Ltd. published this content on 08 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 March 2022 12:52:13 UTC.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
Chunghwa Chemical Synthesis & Biotech : Resolution of the Board of Directors for convening the 2022 Annual General Shareholders' Meeting. (Adding Matters for Discussion)
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. 
